Description

Spartan 1 Vials (Mod GRF 1-29/CJC-1295 No Dac + Hexarelin)

Spartan 1 peptide is made of 5mg of Mod GRF 1-29/CJC-1295 No Dac and 5mg of Hexarelin, totaling 10mg.

Mod grf 1-29/CJC-1295 No Dac
CAS Number	86168-78-7
Molar Mass	3357.93 g·mol−1
Chemical Formula	C149H246N44O42S
IUPAC Name	L-Tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide

Hexarelin
CAS Number	140703-51-1
Molar Mass	887.059 g·mol−1
Chemical Formula	C47H58N12O6
IUPAC Name	(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide

Introduction

Spartan 1, a cutting-edge research peptide combining Mod GRF 1-29 (CJC-1295 No Dac) and Hexarelin, is explicitly intended for research purposes. This peptide blend is designed to be investigated within controlled laboratory settings to unravel its unique characteristics and potential applications in the realm of growth hormone regulation.

Key Characteristics

Spartan 1 distinguishes itself with a unique composition featuring Mod GRF 1-29 (CJC-1295 No Dac) and Hexarelin. Each component contributes distinct properties, making this peptide combination a subject of scientific interest for researchers delving into growth hormone modulation and associated physiological mechanisms.

Research Applications

The primary research focus for Spartan 1 lies in its potential to regulate growth hormone levels and influence various metabolic processes. Researchers employ this peptide blend to explore its impact on growth hormone deficiency, potential synergistic effects, and Hexarelin’s role in activating the GH secretagogue receptor.

Research Benefits

Synergistic Effects

Spartan 1 is under scrutiny for potential synergistic effects resulting from the combination of Mod GRF 1-29 (CJC-1295 No Dac) and Hexarelin. Scientific investigations aim to uncover how these peptides, when combined, may exhibit cooperative actions, enhancing the overall regulatory effects on growth hormone secretion.

CJC 1295 No DAC and Treatment of Growth Hormone Deficiency

Researchers are exploring the specific benefits of CJC-1295 No Dac in addressing growth hormone deficiency. Scientific inquiries aim to elucidate the peptide’s role in regulating growth hormone levels and its potential therapeutic applications in cases of deficiency.

Hexarelin Activates the GH Secretagogue Receptor

Studies delve into Hexarelin’s unique ability to activate the GH secretagogue receptor. Researchers seek to understand how Hexarelin’s interaction with this receptor may influence growth hormone secretion and its potential implications for therapeutic research.

Summary

In summary, Spartan 1 (Mod GRF 1-29/CJC-1295 No Dac + Hexarelin) presents itself as a valuable research tool, providing researchers with the opportunity to explore the synergistic effects and individual benefits of its components. This peptide combination holds promise in contributing to the understanding of growth hormone regulation and potential therapeutic applications.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019 Jun;11(6):804-812. doi: 10.1002/dta.2554. Epub 2018 Dec 25. PMID: 30489688. [Read More].

Torsello A, Grilli R, Luoni M, Guidi M, Ghigo MC, Wehrenberg WB, Deghenghi R, Müller EE, Locatelli V. Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. Eur J Endocrinol. 1996 Oct;135(4):481-8. doi: 10.1530/eje.0.1350481. PMID: 8921832. [Read More].